Insight

FRAME Trial Shows Avutometinib and Defactinib Could Successfully Treat Low-Grade Serous Ovarian Cancer – ICR

Collage photo of Susana Banerjee and Udai Banerji

Jun 29, 2025, 14:15

FRAME Trial Shows Avutometinib and Defactinib Could Successfully Treat Low-Grade Serous Ovarian Cancer – ICR

The Institute of Cancer Research (ICR) shared a post on LinkedIn about a paper by Susana Banerjee et al. published in Nature Medicine:

“New.

Results of the FRAME trial, which showed that avutometinib and defactinib could be used to successfully treat low-grade serous ovarian cancer, have been published in the journal Nature Medicine.

The FDA has already granted accelerated approval for this combination, marking the first approved therapy for low-grade serous ovarian cancer – a rare and historically hard-to-treat cancer.

Professor Udai Banerji, Co-Director of Drug Development at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, who led the preclinical and clinical development of the drug combination that led up to the FRAME trial, said: We used findings from multiple experimental approaches including the study of phosphoproteins and use of cancer cells from patients grown in the labs called ‘organoids’ to devise this combination.”

Read the publication in full.”

Title: Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial

Authors: Susana Banerjee, Matthew G. Krebs, Alastair Greystoke, Alvaro Ingles Garces, Vicky Sanchez Perez, Angelika Terbuch, Rajiv Shinde, Reece Caldwell, Rafael Grochot, Mahtab Rouhifard, Ruth Ruddle, Bora Gurel, Karen Swales, Nina Tunariu, Toby Prout, Mona Parmar, Stefan Symeonides, Jan Rekowski, Christina Yap, Adam Sharp, Alec Paschalis, Juanita Lopez, Anna Minchom, Johann Sebastian de Bono, Udai Banerji

FRAME Trial Shows Avutometinib and Defactinib Could Successfully Treat Low-Grade Serous Ovarian Cancer - ICR

You can read the Full Article in Nature Medicine.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Insight

OncoDaily

Insight

FRAME Trial Shows Avutometinib and Defactinib Could Successfully Treat Low-Grade Serous Ovarian Cancer – ICR

“New.

Results of the FRAME trial, which showed that avutometinib and defactinib could be used to successfully treat low-grade serous ovarian cancer, have been published in the journal Nature Medicine.

The FDA has already granted accelerated approval for this combination, marking the first approved therapy for low-grade serous ovarian cancer – a rare and historically hard-to-treat cancer.

Read the publication in full.”